Cellaria

Cellaria develops and markets patient-specific cell model systems for disease research and drug screening. Their technology enables more personalized assessment of drug response by using cells derived directly from patients with diseases such as cancer or diabetes. Their products include advanced media formulations and extracellular matrix scaffolds that support complex organoid cultures mimicking human disease states. The company’s solutions have demonstrated value in preclinical studies but do not themselves constitute clinical-stage therapeutics. Their main impact is accelerating translational research by providing actionable biological models that better represent patient heterogeneity than traditional methods. There are no reported clinical trials or marketed drugs associated with Cellaria itself—its role is as a provider of enabling technologies for pharmaceutical R&D.